Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

You’ve supercharged your research process with ACS and Mendeley!

Click to create an ACS ID

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Your Mendeley pairing has expired. Please reconnect
ACS Publications. Most Trusted. Most Cited. Most Read
My Activity

Figure 1Loading Img

Diclofenac and Its Derivatives As Tools for Studying Human Cytochromes P450 Active Sites: Particular Efficiency and Regioselectivity of P450 2Cs

View Author Information
Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, UMR 8601 CNRS, Université Paris V, 45 Rue des Saints-Pères, 75270 Paris Cedex 06, France
Cite this: Biochemistry 1999, 38, 43, 14264–14270
Publication Date (Web):October 9, 1999
Copyright © 1999 American Chemical Society

    Article Views





    Other access options


    A comparison of the oxidations of diclofenac with microsomes of yeasts expressing various human liver cytochromes P450 showed that P450 2C9 regioselectively led to 4‘-hydroxy diclofenac (4‘-OHD) whereas P450 3A4 only led to 5-hydroxy diclofenac (5-OHD). P450 2C19, 2C18, and 2C8 led to the simultaneous formation of 4‘-OHD and 5-OHD (respective molar ratios of 1.3, 0.37, and 0.17), and P450 1A1, 1A2, 2D6, and 2E1 failed to give any detectable hydroxylated metabolite under identical conditions. P450 2C9 was found to be much more efficient for diclofenac hydroxylation than all the other P450s tested (kcat/KM of 1.6 min-1 μM-1 instead of 0.025 for the second more active P450), mainly because of markedly lower KM values (15 ± 8 instead of values between 170 and 630 μM). Oxidation of diclofenac with chemical model systems of cytochrome P450 based on iron porphyrin catalysts exclusively led to the quinone imine derived from two-electron oxidation of 5-OHD, in an almost quantitative yield. Two derivatives of diclofenac lacking its COO- function were then synthesized; their oxidation by recombinant human P450 2Cs always led to a major product coming from their 5-hydroxylation. Substrate 2, which derives from reduction of the COO- function of diclofenac to the CH2OH function, was studied in more detail. All the P450s tested (1A1, 1A2, 2C8, 2C9, 2C18, 2C19, 2D6, and 3A4) almost exclusively led to its 5-hydroxylation. P450s of the 2C subfamily were found to be the most efficient catalysts for this reaction, with kcat/KM values between 0.2 and 1.6 min-1 μM-1. Oxidation of 2 with an iron porphyrin-based chemical model of cytochrome P450 also led to a product derived from the oxidation of 2 at position 5. These results show that oxidation of diclofenac and its derivative 2, either with chemical model systems of cytochrome P450 or with recombinant human P450s, generally occurs at position 5. This position, para to the NH group on the more electron-rich aromatic ring of diclofenac derivatives, is thus, as expected, the priviledged site of reaction of electrophilic, oxidant species. The most spectacular exception to this chemoselective 5-oxidation of diclofenac derivatives was found for oxidation of diclofenac itself with P450 2C9 (and P450 2C19 and 2C18 to a lesser extent), which only led to 4‘-OHD. A likely explanation for this result is a strict positioning of diclofenac in the P450 2C9 active site, via its COO- function, to completely orientate its hydroxylation toward position 4‘, which is not chemically preferred. P450 2C19, 2C18, and 2C8 would not lead to such a strict positioning as they give mixtures of 4‘-OHD and 5-OHD. The above results show that diclofenac derivatives are interesting tools to compare the active site topologies of human P450 2Cs.

    Read this article

    To access this article, please review the available access options below.

    Get instant access

    Purchase Access

    Read this article for 48 hours. Check out below using your ACS ID or as a guest.


    Access through Your Institution

    You may have access to this article through your institution.

    Your institution does not have access to this content. You can change your affiliated institution below.


     To whom correspondence should be addressed. Telephone:  01-42-86-21-87. Fax:  33-1-42 86 83 87. E-mail: [email protected].

    Cited By

    This article is cited by 65 publications.

    1. Rasmus Leth, Bogac Ercig, Lars Olsen, Flemming Steen Jørgensen. Both Reactivity and Accessibility Are Important in Cytochrome P450 Metabolism: A Combined DFT and MD Study of Fenamic Acids in BM3 Mutants. Journal of Chemical Information and Modeling 2019, 59 (2) , 743-753.
    2. Philip M. Cox and Namandjé N. Bumpus . Structure–Activity Studies Reveal the Oxazinone Ring Is a Determinant of Cytochrome P450 2B6 Activity Toward Efavirenz. ACS Medicinal Chemistry Letters 2014, 5 (10) , 1156-1161.
    3. Richard Lonsdale, Kerensa T. Houghton, Jolanta Żurek, Christine M. Bathelt, Nicolas Foloppe, Marcel J. de Groot, Jeremy N. Harvey, and Adrian J. Mulholland . Quantum Mechanics/Molecular Mechanics Modeling of Regioselectivity of Drug Metabolism in Cytochrome P450 2C9. Journal of the American Chemical Society 2013, 135 (21) , 8001-8015.
    4. Ya-Wen Hsiao, Carl Petersson, Mats A. Svensson, and Ulf Norinder . A Pragmatic Approach Using First-Principle Methods to Address Site of Metabolism with Implications for Reactive Metabolite Formation. Journal of Chemical Information and Modeling 2012, 52 (3) , 686-695.
    5. Andrea Fantuzzi, Lok Hang Mak, Ennio Capria, Vikash Dodhia, Paola Panicco, Stephen Collins, and Gianfranco Gilardi . A New Standardized Electrochemical Array for Drug Metabolic Profiling with Human Cytochromes P450. Analytical Chemistry 2011, 83 (10) , 3831-3839.
    6. Poongavanam Vasanthanathan, Jozef Hritz, Olivier Taboureau, Lars Olsen, Flemming Steen Jørgensen, Nico P. E. Vermeulen and Chris Oostenbrink . Virtual Screening and Prediction of Site of Metabolism for Cytochrome P450 1A2 Ligands. Journal of Chemical Information and Modeling 2009, 49 (1) , 43-52.
    7. Christine M. Bathelt, Adrian J. Mulholland and Jeremy N. Harvey. QM/MM Modeling of Benzene Hydroxylation in Human Cytochrome P450 2C9. The Journal of Physical Chemistry A 2008, 112 (50) , 13149-13156.
    8. Patrik Rydberg, Ulf Ryde and Lars Olsen. Prediction of Activation Energies for Aromatic Oxidation by Cytochrome P450. The Journal of Physical Chemistry A 2008, 112 (50) , 13058-13065.
    9. Myint Myint Sein , Marco Zedda , Jochen Tuerk , Torsten C. Schmidt , Alfred Golloch , and Clemens von Sonntag . Oxidation of Diclofenac with Ozone in Aqueous Solution. Environmental Science & Technology 2008, 42 (17) , 6656-6662.
    10. Rana Azeem Ashraf, Matthias Bureik, Mario Andrea Marchisio. Design and engineering of logic genetic-enzymatic gates based on the activity of the human CYP2C9 enzyme in permeabilized Saccharomyces cerevisiae cells. Synthetic and Systems Biotechnology 2024, 9 (3) , 406-415.
    11. Slobodan P. Rendic, F. Peter Guengerich. Formation of potentially toxic metabolites of drugs in reactions catalyzed by human drug-metabolizing enzymes. Archives of Toxicology 2024, 98 (6) , 1581-1628.
    12. Yuya Yogo, Kaori Yasuda, Teisuke Takita, Kiyoshi Yasukawa, Yuichiro Iwai, Miyu Nishikawa, Hiroshi Sugimoto, Shinichi Ikushiro, Toshiyuki Sakaki. Metabolism of non-steroidal anti-inflammatory drugs (NSAIDs) by Streptomyces griseolus CYP105A1 and its variants. Drug Metabolism and Pharmacokinetics 2022, 45 , 100455.
    13. Slobodan P. Rendic, F. Peter Guengerich. Human Family 1–4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update. Archives of Toxicology 2021, 95 (2) , 395-472.
    14. Yolanda Macías, Javier Gómez Tabales, Elena García-Martín, José A.G. Agúndez. An update on the pharmacogenomics of NSAID metabolism and the risk of gastrointestinal bleeding. Expert Opinion on Drug Metabolism & Toxicology 2020, 16 (4) , 319-332.
    15. Muhammad Usman, Zhu Zhen-Han, Chang Ze-Na, Han Jun-Ping, Qian Wen, Yang Chang-Qing, Nishikawa Miyu, Sakaki Toshiyuki. Effect of iguratimod on diclofenac metabolism by CYP2C9 in rats and human recombinant CYP2C9 yeast cells. Brazilian Journal of Pharmaceutical Sciences 2019, 55
    16. Liyun Ma, Xiaojing Mao, Xiao Sun, Li Xu. Biotransformation of NSAIDs by pig liver microsomes in vitro: Kinetics, metabolites identification and toxicity prediction. Chemosphere 2017, 186 , 466-474.
    17. Qiushi Xie, Yang Chen, Fei Liu, Zeyu Zhong, Kaijing Zhao, Zhaoli Ling, Fan Wang, Xiange Tang, Zhongjian Wang, Li Liu, Xiaodong Liu. Interspecies differences in metabolism of deoxypodophyllotoxin in hepatic microsomes from human, monkey, rat, mouse and dog. Drug Metabolism and Pharmacokinetics 2016, 31 (4) , 314-322.
    18. Ying-Lu Cui, Fang Xu, Rongling Wu. Molecular dynamics investigations of regioselectivity of anionic/aromatic substrates by a family of enzymes: a case study of diclofenac binding in CYP2C isoforms. Physical Chemistry Chemical Physics 2016, 18 (26) , 17428-17439.
    19. Janne T. Backman, Anne M. Filppula, Mikko Niemi, Pertti J. Neuvonen, . Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. Pharmacological Reviews 2016, 68 (1) , 168-241.
    20. Lian-Hua Xu, Haruo Ikeda, Ling Liu, Takatoshi Arakawa, Takayoshi Wakagi, Hirofumi Shoun, Shinya Fushinobu. Structural basis for the 4′-hydroxylation of diclofenac by a microbial cytochrome P450 monooxygenase. Applied Microbiology and Biotechnology 2015, 99 (7) , 3081-3091.
    21. Harini Venkataraman, Marlies C.A. Verkade-Vreeker, Luigi Capoferri, Daan P. Geerke, Nico P.E. Vermeulen, Jan N.M. Commandeur. Application of engineered cytochrome P450 mutants as biocatalysts for the synthesis of benzylic and aromatic metabolites of fenamic acid NSAIDs. Bioorganic & Medicinal Chemistry 2014, 22 (20) , 5613-5620.
    22. Andrew G. Leach, Nathan J. Kidley. Cytochrome P450 Substrate Recognition and Binding. 2014, 103-132.
    23. Jan Simon Boerma, Nico P.E. Vermeulen, Jan N.M. Commandeur. One-electron oxidation of diclofenac by human cytochrome P450s as a potential bioactivation mechanism for formation of 2′-(glutathion-S-yl)-deschloro-diclofenac. Chemico-Biological Interactions 2014, 207 , 32-40.
    24. Emanuela Puccinelli, Pier Giovanni Gervasi, Gualtiero Pelosi, Mariarita Puntoni, Vincenzo Longo. Modulation of cytochrome P450 enzymes in response to continuous or intermittent high-fat diet in pigs. Xenobiotica 2013, 43 (8) , 686-698.
    25. Giovanna Di Nardo, Gianfranco Gilardi. Optimization of the Bacterial Cytochrome P450 BM3 System for the Production of Human Drug Metabolites. International Journal of Molecular Sciences 2012, 13 (12) , 15901-15924.
    26. Francesco Rua, Giovanna Di Nardo, Sheila J. Sadeghi, Gianfranco Gilardi. Toward reduction in animal sacrifice for drugs: Molecular modeling of Macaca fascicularis P450 2C20 for virtual screening of Homo sapiens P450 2C8 substrates. Biotechnology and Applied Biochemistry 2012, 59 (6) , 479-489.
    27. Stephen J. Fey, Krzysztof Wrzesinski. Determination of Drug Toxicity Using 3D Spheroids Constructed From an Immortal Human Hepatocyte Cell Line. Toxicological Sciences 2012, 127 (2) , 403-411.
    28. Georgia E. Tsotsou, Anastasia Sideri, Abhineet Goyal, Giovanna Di Nardo, Gianfranco Gilardi. Identification of Mutant Asp251Gly/Gln307His of Cytochrome P450 BM3 for the Generation of Metabolites of Diclofenac, Ibuprofen and Tolbutamide. Chemistry – A European Journal 2012, 18 (12) , 3582-3588.
    29. Kimihiko Sato, Yasushi Yamazoe. Unimolecular and Bimolecular Binding System for the Prediction of CYP2D6-Mediated Metabolism. Drug Metabolism and Disposition 2012, 40 (3) , 486-496.
    30. Shizuo Narimatsu, Ryoko Nakanishi, Nobumitsu Hanioka, Keita Saito, Hiroyuki Kataoka. Characterization of inhibitory effects of perfluorooctane sulfonate on human hepatic cytochrome P450 isoenzymes: Focusing on CYP2A6. Chemico-Biological Interactions 2011, 194 (2-3) , 120-126.
    31. Robert A. Roth, Patricia E. Ganey. Animal models of idiosyncratic drug-induced liver injury—Current status. Critical Reviews in Toxicology 2011, 41 (9) , 723-739.
    32. A. A. Pogrebnoi, M. A. Grishina, V. A. Potemkin, D. A. Sysakov. Modeling complexes of substrates with cytochrome P450 2C9. Pharmaceutical Chemistry Journal 2010, 44 (5) , 237-240.
    33. Emanuela Puccinelli, Pier Giovanni Gervasi, Margherita La Marca, Pascale Beffy, Vincenzo Longo. Expression and inducibility by phenobarbital of CYP2C33, CYP2C42, CYP2C49, CYP2B22, and CYP3As in porcine liver, kidney, small intestine, and nasal tissues. Xenobiotica 2010, 40 (8) , 525-535.
    34. Yasuhiro UNO, Kiyomi MATSUNO, Chika NAKAMURA, Masahiro UTOH, Hiroshi YAMAZAKI. Identification and Characterization of CYP2C18 in the Cynomolgus Macaque (Macaca fascicularis). Journal of Veterinary Medical Science 2010, 72 (2) , 225-228.
    35. Jing Zi, Duan Liu, Pingping Ma, He Huang, Juanli Zhu, Dongqing Wei, Jin Yang, Chao Chen. Effects of CYP2C9*3 and CYP2C9* 13 on Diclofenac Metabolism and Inhibition-based Drug-Drug Interactions. Drug Metabolism and Pharmacokinetics 2010, 25 (4) , 343-350.
    36. Patrik Rydberg, Poongavanam Vasanthanathan, Chris Oostenbrink, Lars Olsen. Fast Prediction of Cytochrome P450 Mediated Drug Metabolism. ChemMedChem 2009, 4 (12) , 2070-2079.
    37. Roland Weis, Margit Winkler, Matthias Schittmayer, Spiros Kambourakis, Mandy Vink, J. David Rozzell, Anton Glieder. A Diversified Library of Bacterial and Fungal Bifunctional Cytochrome P450 Enzymes for Drug Metabolite Synthesis. Advanced Synthesis & Catalysis 2009, 351 (13) , 2140-2146.
    38. David J. Elliot, Suharjono, Benjamin C. Lewis, Elizabeth M. J. Gillam, Donald J. Birkett, Annette S. Gross, John O. Miners. Identification of the human cytochromes P450 catalysing the rate‐limiting pathways of gliclazide elimination. British Journal of Clinical Pharmacology 2007, 64 (4) , 450-457.
    39. Pierre Lafite, Sylvie Dijols, Darryl C. Zeldin, Patrick M. Dansette, Daniel Mansuy. Selective, competitive and mechanism-based inhibitors of human cytochrome P450 2J2. Archives of Biochemistry and Biophysics 2007, 464 (2) , 155-168.
    40. Cuyue Tang, Yulin Fang, Catherine Booth-Genthe, Yuhsin Kuo, Scott D. Kuduk, Tom H. Rushmore, Brian A. Carr. Diclofenac hydroxylation in monkeys: Efficiency, regioselectivity, and response to inhibitors. Biochemical Pharmacology 2007, 73 (6) , 880-890.
    41. Constance Bochot, Jean-François Bartoli, Yves Frapart, Patrick M. Dansette, Daniel Mansuy, Pierrette Battioni. Synthesis and spectroscopic, electrochemical, and catalytic properties of a new manganese porphyrin bearing four positive charges close to the metal. Journal of Molecular Catalysis A: Chemical 2007, 263 (1-2) , 200-205.
    42. C.W. Murray, M.J. Hartshorn. New Applications for Structure-Based Drug Design. 2007, 775-806.
    43. Jeremy N. Harvey, Christine M. Bathelt, Adrian J. Mulholland. QM/MM modeling of compound I active species in cytochrome P450, cytochrome C peroxidase, and ascorbate peroxidase. Journal of Computational Chemistry 2006, 27 (12) , 1352-1362.
    44. James J Cali, Dongping Ma, Mary Sobol, Daniel J Simpson, Susan Frackman, Troy D Good, William J Daily, David Liu. Luminogenic cytochrome P450 assays. Expert Opinion on Drug Metabolism & Toxicology 2006, 2 (4) , 629-645.
    45. Jeremy N. Harvey, Varinder K. Aggarwal, Christine M. Bathelt, José‐Luis Carreón‐Macedo, Timothy Gallagher, Nicole Holzmann, Adrian J. Mulholland, Raphaël Robiette. QM and QM/MM studies of selectivity in organic and bioorganic chemistry. Journal of Physical Organic Chemistry 2006, 19 (8-9) , 608-615.
    46. Pierre Lafite, Sylvie Dijols, Didier Buisson, Anne-Christine Macherey, Darryl C. Zeldin, Patrick M. Dansette, Daniel Mansuy. Design and synthesis of selective, high-affinity inhibitors of human cytochrome P450 2J2. Bioorganic & Medicinal Chemistry Letters 2006, 16 (10) , 2777-2780.
    47. Christine M. Bathelt, Jolanta Zurek, Adrian J. Mulholland, Jeremy N. Harvey. Electronic Structure of Compound I in Human Isoforms of Cytochrome P450 from QM/MM Modeling. Journal of the American Chemical Society 2005, 127 (37) , 12900-12908.
    48. Carmen Martínez, Elena García‐Martín, Gerardo Blanco, Francisco J. G. Gamito, José M. Ladero, José A. G. Agúndez. The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)‐ibuprofen enantiomer in healthy subjects. British Journal of Clinical Pharmacology 2005, 59 (1) , 62-68.
    49. Julia Kirchheiner, Martina Tsahuridu, Wafaa Jabrane, Ivar Roots, Jürgen Brockmöller. The CYP2C9 polymorphism: from enzyme kinetics to clinical dose recommendations. Personalized Medicine 2004, 1 (1) , 63-84.
    50. Katalin Monostory, Eszter Hazai, László Vereczkey. Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chemico-Biological Interactions 2004, 147 (3) , 331-340.
    51. Delphine Mathieu, Jean François Bartoli, Pierrette Battioni, Daniel Mansuy. Monooxygenation of aromatic compounds by dioxygen with bioinspired systems using non-heme iron catalysts and tetrahydropterins: comparison with other reducing agents and interesting regioselectivity favouring meta-hydroxylation. Tetrahedron 2004, 60 (17) , 3855-3862.
    52. N. J. Proctor, G. T. Tucker, A. Rostami-Hodjegan. Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica 2004, 34 (2) , 151-178.
    53. Mark J.I. Paine, Lesley A. McLaughlin, Jack U. Flanagan, Carol A. Kemp, Michael J. Sutcliffe, Gordon C.K. Roberts, C. Roland Wolf. Residues Glutamate 216 and Aspartate 301 Are Key Determinants of Substrate Specificity and Product Regioselectivity in Cytochrome P450 2D6. Journal of Biological Chemistry 2003, 278 (6) , 4021-4027.
    54. Armelle Melet, Nadine Assrir, Pascale Jean, Maria Pilar Lopez-Garcia, Cristina Marques-Soares, Maryse Jaouen, Patrick M Dansette, Marie-Agnès Sari, Daniel Mansuy. Substrate selectivity of human cytochrome P450 2C9: importance of residues 476, 365, and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid. Archives of Biochemistry and Biophysics 2003, 409 (1) , 80-91.
    55. Poh-Sing Ng, Susumu Imaoka, Toyoko Hiroi, Mayuko Osada, Toshio Niwa, Tetsuya Kamataki, Yoshihiko Funae. Production of Inhibitory Polyclonal Antibodies against Cytochrome P450s. Drug Metabolism and Pharmacokinetics 2003, 18 (3) , 163-172.
    56. Julia Kirchheiner, Ingolf Meineke, Nadine Steinbach, Christian Meisel, Ivar Roots, Jürgen Brockmöller. Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. British Journal of Clinical Pharmacology 2003, 55 (1) , 51-61.
    57. Toshiro Niwa, Akira Kageyama, Kae Kishimoto, Yoshiyasu Yabusaki, Fumihide Ishibashi, Masanao Katagiri. Amino Acid Residues Affecting the Activities of Human Cytochrome P450 2C9 and 2C19. Drug Metabolism and Disposition 2002, 30 (8) , 931-936.
    58. Slobodan Rendic. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metabolism Reviews 2002, 34 (1-2) , 83-448.
    59. Jian Zhu-Ge. Establishment of a transgenic cell line stably expressing human cytochrome P450 2C18 and identification of a CYP2C18 clone with exon 5 missing. World Journal of Gastroenterology 2002, 8 (5) , 888.
    60. Marianne Ridderström, Ismael Zamora, Ola Fjellström, Tommy B. Andersson. Analysis of Selective Regions in the Active Sites of Human Cytochromes P450, 2C8, 2C9, 2C18, and 2C19 Homology Models Using GRID/CPCA. Journal of Medicinal Chemistry 2001, 44 (24) , 4072-4081.
    61. Nguyêt-Thanh Ha-Duong, Cristina Marques-Soares, Sylvie Dijols, Marie-Agnès Sari, Patrick M. Dansette, Daniel Mansuy. Interaction of New Sulfaphenazole Derivatives with Human Liver Cytochrome P450 2Cs: Structural Determinants Required for Selective Recognition by CYP 2C9 and for Inhibition of Human CYP 2Cs. Archives of Biochemistry and Biophysics 2001, 394 (2) , 189-200.
    62. Nguyêt-Thanh Ha-Duong, Sylvie Dijols, Cristina Marques-Soares, Claire Minoletti, Patrick M. Dansette, Daniel Mansuy. Synthesis of Sulfaphenazole Derivatives and Their Use as Inhibitors and Tools for Comparing the Active Sites of Human Liver Cytochromes P450 of the 2C Subfamily. Journal of Medicinal Chemistry 2001, 44 (22) , 3622-3631.
    63. . References. 2001, 164-210.
    64. Wouter A Duetz, Jan B Van Beilen, Bernard Witholt. Using proteins in their natural environment: potential and limitations of microbial whole-cell hydroxylations in applied biocatalysis. Current Opinion in Biotechnology 2001, 12 (4) , 419-425.
    65. Samya Othman, Virginie Mansuy-Mouries, Claude Bensoussan, Pierrette Battioni, Daniel Mansuy. Hydroxylation of diclofenac: an illustration of the complementary roles of biomimetic metalloporphyrin catalysts and yeasts expressing human cytochromes P450 in drug metabolism studies. Comptes Rendus de l'Académie des Sciences - Series IIC - Chemistry 2000, 3 (9) , 751-755.